Vaxcyte CEO Disposes Shares for Tax Withholding; Investors Should Focus on Upcoming Clinical Data
Grant Pickering, CEO of Vaxcyte (NASDAQ:PCVX), sold 6,289 shares to cover tax obligations following the vesting of restricted stock units. The transaction was non-discretionary and had a value of approximately $384,900 based on an average sale price of $61.20 per share. Post-transaction, Pickering holds around 713,400 shares directly and indirectly in his name or through trusts for his children. Vaxcyte's stock has delivered a strong total return of 95% over the past year as of August 31, reflecting investor confidence in its clinical pipeline. The company is currently focused on developing VAX-24, an experimental pneumococcal conjugate vaccine targeting invasive disease and pneumonia. Investors are advised to monitor upcoming data from pivotal trials such as OPUS-1 for VAX-31, a 31-strain pneumococcal vaccine being tested against Prevnar 20 (Pfizer) and Capvaxive (Merck). Topline results are expected in Q4 2026 with additional data anticipated by mid-2027.
Tickers: $PCVX
Topics: ceo stock_transaction tax_withholding